The biotech companies Pfizer Inc. (PFE) and BioNTech SE (BNTX), which have developed a COVID-19 vaccine, are now one step closer to their full development approval. This month, the companies obtained FDA clearance for emergency use of their BNT162b2 anti-Covid vaccine during the pandemic.
It should be remembered that the authorization for emergency use is not the full authorization of the regulator. However, Pfizer and BioNTech will now be able to sell their BNT162b2 vaccine in the United States to treat individuals aged 16 and over. Companies must submit another application to the FDA in order to get full approval, which would include additional safety data from study participants. Specialists are allowed to track vaccinated patients for a period of just two months after receiving the second dose as part of the new authorization.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The Ministry of Health of Canada also this month approved the use of the vaccine COVID-19, produced by Pfizer and BioNTech. By the end of this year, in order to begin prevention in the most vulnerable communities, the country expects to obtain around 250,000 doses of the vaccine. Since the beginning of December, Pfizer and BioNTech in the UK have been using the vaccine. The first negative episodes were already noted there: two individuals had anaphylactic shock after vaccination, and one allergic reaction report was also received.
The FDA also in the last week gave a go ahead to Moderna Inc. (MRNA) for approval of the mRNA-1273 vaccine. The Agency published its analysis of the data. Moderna also received the same approval for its vaccine as has already been obtained by that of Pfizer and BioNTech.
But shares of the all three companies became victim of profit taking and have been declined since the day their vaccines began to be used for mass vaccination. Since start of emergency use of their vaccine on December 14, Pfizer Inc. (PFE) and BioNTech SE (BNTX) stocks are down -8.95% and -21.40%, respectively; whereas shares of Moderna (MRNA) are down -7.05% since its vaccine began to administer from Dec 21.